Photopharmics
PhotoPharmics: A clinical-stage medical device company innovating treatments for neurodegenerative disorders.
- 7
- Company
- Lehi, UT, USUnited States
PhotoPharmics: A clinical-stage medical device company innovating treatments for neurodegenerative disorders.
photopharmics.comCrawled Oct 14, 2026
PhotoPharmics is available for scientific exchange as its pivotal study approaches completion. A data readout is anticipated at the World Parkinson Congress.
The company aims to improve the lives of people with neurodegenerative diseases through rigorous science and therapies. Its team has experience in scientific, clinical, commercial, and leadership roles, as well as expertise in medical technology and neurodegenerative diseases.
Celeste is an investigational device being studied to better understand the role of retinal and circadian signaling pathways in Parkinson’s disease.
Celeste Therapeutics finishes a pivotal trial assessing its at-home light therapy device for Parkinson’s disease. The study included the final patient visit, marking completion of the clinical evaluation. The device targets motor symptoms through non-invasive light exposure.
May 2026Parkinson's News TodayNews article
PhotoPharmics finishes a **351-patient Phase 3 trial** for its **Celeste® photo-neuromodulation program**, targeting Parkinson’s disease (PD). The company will present topline results at the **World PD Congress** in Phoenix. This milestone advances the investigational therapy’s development pipeline.
May 2026The National Law ReviewNews article
PhotoPharmics adds clinical, regulatory, and capital-markets experts to its board as its Phase 3 Parkinson’s disease trial completes enrollment. The company now stands ready to submit findings to the FDA and pursue strategic partnerships. The trial’s full enrollment marks a key milestone ahead of top-line results.
Dec 2025TechBuzz NewsNews article
Photopharmics secures a $6 million Series B extension to develop a light-based therapy for Parkinson’s disease. The funding supports ongoing clinical trials, bringing the treatment closer to FDA submission. The company focuses on non-invasive optical interventions for neurological symptom management.
Apr 2025Longevity.TechnologyNews article